MACOR, PAOLO

MACOR, PAOLO  

Dipartimento di Scienze della Vita  

Settore MED/04 - Patologia Generale  

Docenti di ruolo di IIa fascia  

Mostra records
Risultati 1 - 20 di 72 (tempo di esecuzione: 0.024 secondi).
Titolo Data di pubblicazione Autori File
A Human Monoclonal Antibody Against Domain I Of beta 2-Glycoprotein I prevents Clotting and Fetal Loss Induced By Polyclonal Anti-Phospholipid Antibodies In Animal Models. 1-gen-2013 Agostinis, CDURIGUTTO, PAOLOSBLATTERO, DANIELEBULLA, ROBERTAMACOR, PAOLO +
A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles 1-gen-2015 CAPOLLA, SARAMEZZAROBA, NELLYZORZET, SONIAGRANZOTTO, MARILENAVITA, FRANCESCAPOZZATO, GABRIELEMACOR, PAOLO +
A non-complement-fixing antibody to  2 glycoprotein I as a novel therapy for antiphospholipid syndrome 1-gen-2014 C. AgostinisDURIGUTTO, PAOLOSBLATTERO, DANIELEBULLA, ROBERTAMACOR, PAOLOTEDESCO, FRANCESCO +
Alterations in trabecular bone μ-architecture and cartilages in rats with antigen-induced arthritis (AIA) resulting from synchrotron-based X-ray imaging analysis 1-gen-2016 PACILÈ, SERENABIFFI, STEFANIAMENK, RALF HENDRIKGARROVO, CHIARADAL MONEGO, SIMEONEARFELLI, FULVIARIGON, LUIGICOLOMBO, FEDERICOMACOR, PAOLOACCARDO, AGOSTINOTROMBA, GIULIANA
An allosteric redox switch in domain V of β2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition 1-gen-2021 Macor, Paolo +
An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. 1-gen-2008 MACOR, PAOLOZORZET, SONIACELEGHINI, CLAUDIOTEDESCO, FRANCESCO +
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers 1-gen-2016 MACOR, PAOLO +
Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System 1-gen-2022 Capolla, SaraBozzer, SaraToffoli, GiuseppeMacor, Paolo +
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. 1-gen-2015 MACOR, PAOLOMEZZAROBA, NELLYZORZET, SONIADURIGUTTO, PAOLOCAPOLLA, SARAMARZARI, ROBERTOTEDESCO, FRANCESCOSBLATTERO, DANIELE +
C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. 1-gen-2009 BOSSI, FLEURBULLA, ROBERTAMACOR, PAOLOTEDESCO, FRANCESCO +
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. 1-gen-2006 MACOR, PAOLOTEDESCO, FRANCESCO +
Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I 1-gen-2020 Durigutto P.MacOr P.Agostinis C.Bossi F.Grossi C. +
Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery 1-gen-2016 MACOR, PAOLODURIGUTTO, PAOLO +
Complement as a biological tool to control tumor growth 1-gen-2018 Macor, PaoloCapolla, SaraTedesco, Francesco
Complement as effector system in cancer immunotherapy. 1-gen-2007 MACOR, PAOLOTEDESCO, FRANCESCO
Complement C1q and C8beta deficiency in an individual with recurrent bacterial meningitis and adult-onset systemic lupus erythematosus-like illness. 1-gen-2008 MACOR, PAOLODURIGUTTO, PAOLOBOSSI, FLEURTEDESCO, FRANCESCO +
Complement in human diseases: Lessons from complement deficiencies. 1-gen-2009 MACOR, PAOLOTEDESCO, FRANCESCO +
Complement system and phagocytosis in a colonial protochordate 1-gen-2020 Drago L.Macor P. +
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination 1-gen-2021 Macor P.Manfredi M.De Maso L.Comi G. +
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59 1-gen-2005 ZILLER, FEDERICAMACOR, PAOLOBULLA, ROBERTASBLATTERO, DANIELEMARZARI, ROBERTOTEDESCO, FRANCESCO